Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Subtotal therapeutic classes — Net revenue

Other product segments

Subtotal dosage forms
$482.3M+11.8%
Oral solid
$175.17M-1.7%
Central nervous system
$95.34M+14.3%
Distribution
$86.93M-12.8%
Other dosage forms
$81.59M+19.7%
Transdermal
$67.04M+64.7%
Auto-Injector
$62.21M-6.6%
Injectable
$56.78M+63.9%
Government label
$50.21M+10.5%
Hormonal / allergy
$42.1M+18.9%
Biosimilar
$29.13M+15.4%
Institutional
$12.11M+19.5%
Other therapeutic classes
$11.85M+36.2%
Oral liquid
$10.37M-42.0%
International
$7.61M+300%
License agreement
$0-100%

Similar metrics at other companies

Installed Building Products logo
IBPNet revenue, Installation — Net revenue
$710.7M-0.7%
Marqeta logo
MQPlatform services revenue, net — Net revenue
$156.23M+18.5%
Visa logo
VOther revenue — Net revenue
$1.5B+45.5%
Visa logo
VService revenue — Net revenue
$4.92B+13.7%
Cavco Industries logo
CVCODelivery, setup and other revenues — Net revenue
$23.21M-15.9%
Marqeta logo
MQOther services revenue — Net revenue
$9.57M+32.8%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×—
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Central nervous system95,34483,425178,727151,035
Hormonal / allergy42,09935,41878,03169,617
Other therapeutic classes11,8528,70025,80215,188
Subtotal therapeutic classes149,295127,543282,560235,840
License agreement—500—500
Total Specialty net revenue149,295128,043282,560236,340
AvKARE
Distribution86,93099,663176,079204,558

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported subtotal therapeutic classes — net revenue of $149.3M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue increased by 17.1% year-over-year, from $127.54M to $149.3M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue has grown at a 12.2% compound annual growth rate (CAGR), from $374.12M to $528.01M.
What does subtotal therapeutic classes — net revenue mean?
This metric represents the total net revenue generated from the company's specific therapeutic product categories within its portfolio. It reflects the market demand and commercial performance of these specialized pharmaceutical offerings, excluding returns, discounts, and allowances. Tracking this revenue stream provides insight into the growth trajectory and competitive positioning of the company's core therapeutic focus areas.

Ask your AI about Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude